Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Insulet Acquires Insulin Pump Patents From Bigfoot, AGC

Executive Summary

Insulet will acquire insulin pump patents from Bigfoot Biomedical for $25m, which Bigfoot will use to expand its Unity diabetes management system. Insulet also announced the acquisition of automated insulin delivery assets held by Automated Glucose Control.

You may also be interested in...



Bigfoot Looks To Unlock More Effective Treatments For Type II Diabetics

Bigfoot Biomedical’s Unity system pairs continuous glucose monitoring with smart insulin pen caps, giving patients recommendations on insulin dosing. Because patient interaction is involved, Bigfoot Biomedical can deliver insulin pump-like results to pump-ineligible type II diabetics.

Minute Insight: Insulet Launches Omnipod 5 US-Wide Following Trial Period

After six months, the Omnipod 5 has seen its limited market launch expanded to cover the entirety of the US market.

Medtronic Earns CE Mark For Affera Ablation System, Touts New PFA Results

Results of the PULSED AF trial confirm that Medtronic’s PulseSelect pulsed field ablation is safe and effective for atrial fibrillation ablation. The company will likely incorporate PulseSelect into its Affera cardiac mapping and ablation system, which will soon be available in Europe.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel